Skip to content
PeerVoice Brain & Behaviour Audio cover art

All Episodes

PeerVoice Brain & Behaviour Audio — 70 episodes

#
Title
1

Chongbo Zhao, MD - 探索不断变化的 CIDP 治疗格局:专家视角下的补体抑制疗法治疗潜力

2

One Disease, Many Clinical Presentations: Why and How to Spot Acute Hepatic Porphyria in Different Healthcare Settings

3

Silvia Messina, MD, DPhil / Michael Levy, MD, PhD - Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) or Something Else? How to Tell the Difference

4

Mike Sharma, MD, MSc, FRCPC - Deepening the Dialogue on the Latest Data for Factor XIa Inhibition: Is It Time to Shift the Paradigm in Secondary Stroke Prevention?

5

Xin Cheng, MD, PhD - Seeking Solutions in Secondary Stroke Prevention: The Latest Inquiries and Insights on Factor XIa Inhibition

6

Caterina Garone, MD, PhD - From Clinical Clues to a Confirmatory Diagnosis: Recognising Thymidine Kinase 2 Deficiency Across the Age Spectrum

7

Ashkan Shoamanesh, MD, FRCPC - Turning Pathophysiologic Promise Into Evidence-Based Potential: Are Factor XIa Inhibitors Ready for Prime Time in Secondary Stroke Prevention?

8

Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

9

Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact

10

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

11

James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG

12

Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis

13

Bernhard Suter, MD - Rett Syndrome Uncovered: An International Exchange on Recognition, Monitoring, and Emerging Therapies

14

Richard B. Lipton, MD - Overcoming the Disconnects Between Recommendations and Reality in Acute Migraine Treatment: Patient and Provider Perspectives on Communication and Collaboration

15

Richard A. Lewis, MD - Navigating the Evolving CIDP Treatment Landscape: Expert Perspectives on the Therapeutic Potential of Complement Inhibition

16

Heinz Wiendl, MD - Neurology Updates From the European Meeting in Helsinki (June 2025)

17

Angela Kay Fitch, MD, FACP, MFOMA - Separating Signal From Noise: Overcoming the Challenges of Obesity Management in Real-World Clinical Practice

18

Saiju Jacob, MD, DPhil, FRCP, FAAN - The Value of Disease Control in gMG: The Latest Data Evaluating Patient Needs and Treatment Outcomes as They Emerge From Helsinki

19

Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies

20

Luis Querol, MD, PhD - 2025 Congress Highlights From Edinburgh, Scotland: Breaking Down the Data Driving Novel Therapeutic Developments in CIDP

21

Ashkan Shoamanesh, MD, FRCPC - Can We Find a New Way Forward in Secondary Stroke Prevention? Exploring the Rationale and Potential Roles for Factor XIa Inhibition

22

Heinz Wiendl, MD - Myasthenia Gravis Under the Microscope: 2025 Insights From The Hague

23

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

24

Mike Sharma, MD, MSc, FRCPC - Can We Set a New Standard of Care for Secondary Stroke Prevention? Evaluating Current Gaps and Future Goals

25

Gavin Giovannoni, MBBCh, PhD - Navigating and Pioneering High-Efficacy DMT Strategies: Optimizing Patient Outcomes in Multiple Sclerosis

26

James F. Howard Jr, MD - Beyond FcRn and Complement Inhibitors: Why We Need Novel Treatment Options for Generalized Myasthenia Gravis

27

Elena Pischik, MD, PhD - Acute Polyneuropathy With Abdominal Pain: Could It be Acute Hepatic Porphyria?

28

Serdar Dalkilic, MD - Menstruation Triggering Severe Unexplained Abdominal Pain: Could It Be Acute Hepatic Porphyria?

29

Olivier Bonnot, MD, PhD - Acute Psychosis: When to Suspect Acute Hepatic Porphyria

30

Darren M. Brenner / Benoît Coffin - If I'd Known Then What I Know Now: Recognising My First AHP Patient

31

Darren M. Brenner, MD - If I'd Known Then What I Know Now: Recognising My First AHP Patient (Rebroadcast)

32

Pushpa Narayanaswami, MD, FAAN - Cutting Through the Congress Cacophony on Generalised Myasthenia Gravis: Expert Honing of the Latest Data

33

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

34

Angela Fitch, MD, FACP, MFOMA - This Cannot Weight: A Specialist Guide to Weight Management and Obesity Associated With Emotional Eating Behaviours

35

Bruce A C Cree, MD, PhD, MAS - BTK Inhibition and Beyond: Novel Therapies in MS

36

Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding

37

Jiwon Oh, MD, PhD, FRCPC - Navigating the High-Efficacy DMT Landscape in MS: Integrating New Data and Real-World Evidence

38

Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML

39

Isabel Conceição, MD - Prioritizing Patient-Centered Care for ATTR: Expert Perspectives on the Evolution of Data and Decision-Making

40

Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis

41

Phyllis C. Zee, MD, PhD - Sleep, Heart, Brain: What Promotes and How to Reduce Cardiovascular Risk in Patients With Narcolepsy

42

Michael Thorpy, MD - When Sleep Is Exhausting: Improving Diagnosis and Outcomes in Patients With Idiopathic Hypersomnia

43

Xavier Montalban, MD, PhD - Multiple Sclerosis and Bruton’s Tyrosine Kinase Inhibitors: Therapeutic Potential Beyond Biologics?

44

Ali Aamer Habib, MD - Neuroimmunology Matters: A Specific Review of Emerging Targeted Strategies for Generalised Myasthenia Gravis

45

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

46

Carel le Roux, MD, PhD - Prioritising Obesity Care in Our Clinical Practices: Why We Must and How We Can

47

Laurent Servais, MD, PhD - Catch Them Before They Fall: A Call to Action for Comprehensive Testing for Hypotonia in Paediatric Patients

48

Andreea Ciudin, MD, PhD - Adjusting Our Mindset and Our Approach: Patient and Provider Perspectives on the Modernisation of Obesity Care

49

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers

50

Jacqueline Turner, MSc - Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

51

Nicholas Johnson, MD, MSci, FAAN - Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnosis Is Needed

52

P. James B. Dyck, MD - When ATTR Amyloidosis Strikes a Nerve: Best Practices in Timely Suspicion, Diagnosis, and Management of ATTR-Polyneuropathy

53

Michael Thorpy, MD - Dual Duty: Protecting Cardiovascular Health in Patients With Narcolepsy

54

James F. Howard Jr, MD - Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors

55

Sharon Cohen, MD, FRCPC - Inflammation and the Brain: Why We Need To Know More

56

Shimu Khamlichi, BSc, ClinPsyD - Protecting the Mental Health of People Living With HIV

57

Graeme C Black, OBE, DPhil, FRCOphth, FMedSci - Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

58

Janaka Karalliedde, FRCP, PhD - Stroke Prevention in T2DM: The Neuroprotective Benefits of GLP-1 RAs

59

Melanie J. Davies, CBE, FRCP, FMedSci - Proactive Stroke Risk Mitigation Strategies: Taking Aim in Type 2 Diabetes

60

Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

61

Managing Generalised Myasthenia Gravis: A Tale of Two Targets

62

The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease

63

Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World

64

Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

65

Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?

66

Suspecting and Diagnosing Inherited Retinal Dystrophies: Early Clues and Confirmatory Testing

67

Evolving Therapies in Multiple Sclerosis: BTK Inhibitors